Gadolinium Lawyer

The U.S. Food and Drug Administration (FDA) first notified health care professionals and the public about the gadolinium-related risks for NSF in June 2006 and updated the information in December.When patients undergo an MRI, gadolinium-based contrast agents are commonly used to improve the visibility of internal structures. Five gadolinium-based contrast agents have been approved for use in the

According to reports, the development of NSF can follow a single and or multiple administrations of the gadolinium-based contrast agents. The reports have not always identified a specific agent. The most commonly reported agent was Omniscan, when a specific agent was identified, followed by Magnevist and OptiMARK. NSF has also developed after the sequential administration of Omniscan and MultiHance and Omniscan and ProHance. Because reports do not completely describe exposure to gadolinium-based contrast agents, it is not possible to know if the extent of risks for developing NSF is the same for all agents. Patients should be screened for kidney problems prior to receiving one of these imaging agents. The recommended dose should not be exceeded and enough time should elapse to ensure that a dose has been eliminated from the body before the agent is used again.No cases have been reported of NSF among patients with normal kidney function or those with mild-to-moderate kidney insufficiency.  To learn more, please contact a Gadolinium Lawyer at Williams Kherkher by calling 1.800.220.9341.